Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lantheus Holdings, Inc. to Present at 24th Annual Credit Suisse Healthcare Conference

LNTH

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), today announced that it will be participating in the 24th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 in Scottsdale, Arizona. Mary Anne Heino, President and Chief Executive Officer, and John Bakewell, Chief Financial Officer, will represent the Company in a session scheduled at 8:30 a.m. (Mountain Standard Time).

To access a live webcast of the presentation, please visit the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts, and has offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

Lantheus Holdings, Inc.
Investor Relations
John Bakewell, 978-436-7073
or
Media Relations
Meara Murphy, 978-671-8508